

Date: 11/11/2022

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Script Code : 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Script Code : BAJAJHCARE
--	---

Dear Sir/Madam,

Sub : Outcome of Board Meeting & submission of Unaudited Financial Results for the quarter/half year ended September 30, 2022.

The Board of Directors at its Meeting held today has inter alia, considered and approved the following:

- The unaudited Financial Statements for the quarter/half year ended September 30, 2022, as recommended by the Audit Committee; and

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, we enclose the following:

- (i) Unaudited Financial Results for the quarter/half year ended September 30, 2022 along with limited review report;

The above information is also available on the Company's website at www.bajajhealth.com. This is for your information and records.

We wish to inform you that Board Meeting commenced today at 02.00 p.m. and concluded at 03.45 p.m.

Kindly take the same on record.

Thanking you,

**For and on behalf of Board of Directors
of Bajaj Healthcare Limited**


Mr. Aakash Keshari
Company Secretary



BAJAJ HEALTHCARE LIMITED

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, Road No. 23, Above ICICI Bank, Wagle Industrial Estate, Thane(W) - 400604

• Tel: +91 22 6617 7400 - 499 • Fax : +91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892

Chaturvedi & Agrawal


Chartered Accountants

Independent Auditor's Review Report on the Quarterly and Half Yearly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Bajaj Healthcare Limited (the "Company") for the quarter and Half Year ended September 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Chaturvedi & Agrawal
Chartered Accountants
FRN: 101717W



Rasik Chaturvedi
M. no: 039524

UDIN: 220395248CVJ163977



Date: 11th November 2022
Place: Thane

BAJAJ HEALTHCARE LIMITED
(CIN No. : L99999MH1993PLC072892)
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON September 30, 2022
(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from operations	20,089.37	17,206.88	15,091.25	37,296.26	33,660.13	67,988.98
II. Other Income	13.16	66.99	11.84	80.15	79.79	144.41
III. Total Revenue (I+II)	20,102.53	17,273.88	15,103.09	37,376.41	33,739.92	68,133.39
IV. Expenses						
(a) Cost of materials consumed (Including Other Direct Expenses)	16,501.12	15,215.24	11,498.42	31,716.36	26,942.66	49,982.29
(b) Changes in Inventories of Finished Good	-1,693.68	(2,204.39)	(699.72)	(3,898.07)	(2,692.28)	(377.00)
(c) Employee benefits expense	1,358.72	992.05	929.08	2,350.77	1,893.42	4,110.87
(d) Finance Costs	495.14	382.48	249.96	877.62	529.29	1,262.38
(d) Depreciation and amortisation expense	647.76	653.29	440.74	1,301.06	853.81	1,763.66
(e) Other expenses	591.66	619.63	466.93	1,211.28	1,269.98	2,422.72
Total Expenses	17,900.72	15,658.30	12,885.41	33,559.02	28,796.89	59,164.93
V. Profit Before Tax	2,201.81	1,615.57	2,217.68	3,817.38	4,943.03	8,968.46
VI. Tax Expense						
(a) Current tax	573.00	426.00	454.00	999.00	1,268.00	2,250.00
(b) Earlier Years	-	-	2.13	-	2.04	(358.73)
(c) Deferred Tax	(7.07)	(12.30)	36.40	-19.37	26.13	(61.40)
Total Tax Expenses	565.93	413.70	492.53	979.63	1,296.17	1,829.87
VII. Profit (Loss) for the Period	1,635.87	1,201.88	1,725.15	2,837.75	3,646.86	7,138.59
VIII. Other comprehensive Income						
(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	9.23
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	(2.32)
(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the Period	1,635.87	1,201.88	1,725.15	2,837.75	3,646.86	7,145.49
IX. Paid-up Equity Share Capital (Face Value Rs. 5/-)	1,379.92	1,379.92	1,379.92	1,379.92	1,379.92	1,379.92
X. Other Equity excluding Revaluation Reserve	-	-	-	-	-	31,468.63
XI. Earnings Per Share (Face Value Rs. 5/-) (Not Annualised for Quarter and Half Year Ended)						
(a) Basic (in Rs.)	5.93	4.35	6.25	10.28	13.21	25.87
(b) Diluted (in Rs.)	5.93	4.35	6.25	10.28	13.21	25.87

- Note :**
- a) The above Financial Results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on November 11, 2022
- b) The financial results for the Quarter and Half Year Ended 30th September 2022 have been subjected to limited review by the statutory auditors of the Company.
- c) The above audited financial results for the Quarter Ended September 30, 2022 have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 (Act) read with relevant rules-Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India.
- d) The Statement as per IND AS - 108 on segment reporting is not applicable as the Management has determined that the Company dealing in Bulk Drugs and Formulation as a whole operates under single Chief Operating Decision Maker (CODM) w.e.f April 1st, 2022, pursuant to Organisational Restructuring.
- e) Cash Flow for the Half Year ended September 30, 2022 is given as Annexure I.

By Order of the Board
For Bajaj Healthcare Limited

Sajankumar Bajaj
Chairman and Managing Director
DIN : 00225950



Date: November 11, 2022
Place: Thane

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

Statement Of Assets & Liabilities As At September 30, 2022

(Rs in Lakhs)

Particulars	As at	As at
	September 30, 2022	March 31, 2022
	(Unaudited)	(Audited)
A ASSETS		
Non-current assets		
(a) Property Plant & Equipment	26,206.27	26,974.03
(b) Capital work-in-progress	9,313.38	5,197.58
(c) Financial Assets		
(i) Long Term Investments	0.31	0.31
(ii) Other Financial assets	93.99	107.39
Current assets		
(a) Inventories	18,310.23	15,926.18
(b) Financial Assets		
(i) Trade receivables	22,373.27	18,451.18
(ii) Cash and cash equivalents	1,348.96	197.50
(iii) Other Financial assets	451.91	1,101.58
Other Current assets	4,461.33	4,154.60
TOTAL ASSETS	82,559.64	72,110.34
B EQUITY AND LIABILITIES		
Equity		
(a) Share Capital	1,379.92	1,379.92
(b) Other Equity	34,306.38	31,468.63
Sub - Total - Equity	35,686.30	32,848.55
Liabilities		
Non-Current Liabilities		
Financial Liabilities		
(a) Borrowings	6,540.12	6,631.00
Deffered Tax Liabilities	136.95	156.32
Long-term Provisions	237.18	267.17
Current Liabilities		
Financial Liabilities		
(a) Trade payables	10,099.14	10,492.01
(b) Borrowings	26,912.93	19,042.57
(c) Other Financial liabilities	1,517.41	1,605.14
Other Current Liabilities	163.28	116.55
Provisions	22.88	22.88
Current Tax Liabilities	1,243.46	928.15
TOTAL - EQUITY AND LIABILITIES	82,559.64	72,110.34

By Order of the Board
For Bajaj Healthcare Limited

Sajankumar Bajaj
Chairman and Managing Director

DIN : 00225950



Date: November 11, 2022

Place: Thane

Bajaj Healthcare Limited
Cash Flow Statement for the Half Year ended September 30, 2022
CIN: L99999MH1993PLC072892

Amt (Rs. In Lakhs)

Sr No	Particulars	Half Year Ended September 30, 2022		Year Ended March 31, 2022	
A	<u>CASH FLOW FROM OPERATING ACTIVITIES</u>				
	Net Profit Before Tax		3,817.38		8,968.46
	Adjustments for:				
	Depreciation	1,301.06		1,763.66	
	(Profit)/loss on sale of Assets	(1.28)		1.21	
	Interest & Finance Charges	877.62		1,262.38	
	Interest on FD	(2.81)		(17.17)	
	Provision for Employee Benefits & Leave Enchashment	8.44		95.62	
	Interest Income on Security Deposit	(0.04)		-	
	ECL Provision	45.91	2,228.91	41.51	3,147.22
	Operating Profit before Working Capital Changes		6,046.29		12,115.68
	Adjustments for:				
	(Increase)/Decrease in Other current assets	356.37		(341.64)	
	(Increase)/Decrease In Sundry Debtors	(3,968.01)		(8,604.41)	
	(Increase)/Decrease In Inventories	(2,384.04)		(6,215.15)	
	Increase /(Decrease) in non current and current liabilities	(446.81)		4,077.24	
			(6,442.49)		(11,083.96)
	Cash generated from operations		(396.20)		1,031.72
	Income Tax Paid		(683.67)		(963.12)
	Net Cash flow from Operating activities		(1,079.88)		68.60
B	<u>CASH FLOW FROM INVESTING ACTIVITIES</u>				
	Purchase of Fixed Assets	(551.87)		(7,930.49)	
	(Increase)/Decrease in Capital Wip	(4,115.80)		507.16	
	Sale Of Fixed Assets	19.85		4.35	
	Interest on FD	2.81		17.17	
	Payment to Gratuity Fund	(25.50)		(78.03)	
	Net Cash used in Investing activities		(4,670.51)		(7,479.84)
C	<u>CASH FLOW FROM FINANCING ACTIVITIES</u>				
	Increase /(Decrease) From Long Term Borrowing	481.35		-1,188.24	
	Increase /(Decrease) Of Short Term Borrowing From Bank	7,429.87		8,612.90	
	Increase /(Decrease) Of Borrowing From Director & Inter corpoates	(131.74)		160.35	
	Interest paid	(877.63)		(1,262.38)	
	Dividend Paid	-		(137.99)	
	Net Cash used in financing activities		6,901.85		6,184.63
	Net increase in Cash & Cash Equivalents (A+B+C)		1,151.46		(1,226.60)
	Opening balance of Cash and Cash equivalents as on April 1, 2022		197.50		1,424.11
	Closing balance of Cash and Cash equivalents as on September 30,2022		1,348.96		197.50

For and on behalf of the Board
of Bajaj Healthcare Ltd



Place: Thane
Date: November 11, 2022

Sajankumar Bajaj
Sajankumar Bajaj
Chairman and Managing Director

DIN : 00225950